Cisplatin, carboplatin shortages raise questions about impact on clinical trials 

At least two small biotechs have halt­ed clin­i­cal tri­als due to short­ages of cis­platin and car­bo­platin amid on­go­ing sup­ply is­sues for the chemother­a­pies com­mon­ly used in can­cer care.

Ear­li­er this month, Replimune told in­vestors that it put a Phase II clin­i­cal tri­al on hold un­til sup­ply of both drugs be­comes avail­able. The study is test­ing one of its on­colyt­ic virus­es in com­bi­na­tion with the stan­dard of care in pa­tients with squa­mous cell car­ci­no­ma of the head and neck.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.